Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial

This article was originally published here

The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi

The post Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply